It's not just marketing, Luramist has yet to go through Phase 3 trials. I'm not sure how much that's likely to cost, but with the $50 million they've got Acrux can probably afford to run these itself.
I'd be a bit happier if they partner more products, however, preferably with new partners. At the moment they only have KV (selling Evamist) and Eli Lilly (Axiron and animal health products), having lost Organon and now Vivus.
Now Axiron is out of their hands, I'd like to see Acrux get the rest of the pipeline moving.
- Forums
- ASX - By Stock
- questions
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.6¢

It's not just marketing, Luramist has yet to go through Phase 3...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.524M |
Open | High | Low | Value | Volume |
1.5¢ | 1.6¢ | 1.5¢ | $9.887K | 624.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6355 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6355 | 0.016 |
4 | 559314 | 0.015 |
3 | 420000 | 0.014 |
2 | 397000 | 0.013 |
1 | 80000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 20000 | 1 |
0.018 | 252359 | 2 |
0.019 | 677115 | 3 |
0.020 | 50000 | 1 |
0.021 | 203466 | 1 |
Last trade - 15.00pm 26/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online